| Objective, To aim directly at the patient of chronic of hepatitis B belong to the model of Stagnation of liver-QI with Deficient Spleen, we choose Shuganjianpi prescription, which was a summary from Zuo Jun-ling professor according to his own clinical experience in treating chronic hepatitis B for many years; To observe and contrast randomly, we can offer accurate and reliable evidence in clinical effect of Shuganjianpi prescription; Shuganjianpi prescription not only displays exclusive syndrome needs to be given exclusive treantment, but also offers a shortcut of clinical treantment.Method: 60 patients were divided randomly to two groups named treated group and control group by strictly selective standard, the former group was composed of 30 cases and the latter 30 cases. The treated group was treated with Shuganjianpi prescription plus elementary treatment of Western medicine., while the control group was treated with elementary treatment of Western medicine. Each patient was observed the changes both before and after treatment, such as clinical symptoms, physical signs, hepatic function indexes, abdominal ultrasonography, hepatitis B virus DNA(HBV-DNA), to evaluate the curative effect of Shuganjianpi prescription lowering enzymes, lowering virus quantity, improving clinical symptoms for the patient of Chronic Hepatitis B.Result:1. The total efficiency of the treated group was 90. 00%. And the total efficiency of the control group was 70.00%. There is statistical significance between them (P＜0.05). So there is improving symptomatic curative effect on Shuganjianpi prescription for the patient of Chronic Hepatitis B.2. Clinical symptoms and physical signs were improved markedly in the treated group. Among these, the pain of flank and rib, splenohepatomegalia, expanding of abdomen, inappetence, lacking strength, lassitude andtaciturnity, restlessness and tantrum, eructation, mashed stool are improved significantly(P＜0.01); in the control group, the pain of flank and rib, lacking strength were improved significantly(P＜0.01); After treatment, there is statistical significance between the treated group and the control group regarding expanding of abdomen, inappetence, lassitude and taciturnity, restlessness and tantrum, mashed stool (P＜0.05); there is a little improvement to some extent regarding the pain of flank and rib, splenohepatomegalia, lacking strength, eructation, there is no statistical significance between the two groups (P＞0.05).3. All of the patients of two groups were observed both before treatment and1, 3 months after treatment, The level of the serums ALT decreased gradually during the treatment, There is statistical significance between each group (P＜0.01), So there is efficiency on the treated group and the control group on lowering ALT; There is statistical significance between the treated group and the control group regarding the serums ALTon the 1 and 3 months (P＜0.05), So the treated group is better than the control group, explain that Shuganjianpi prescription has the obvious efficiency on ameliorating the damage of Liver function.4. All of the patients of two groups were observed both before treatment and 1, 3 months after treatment, The level of the ALB increased gradually during the treatment, There is statistical significance between each group, the treated group (P＜0.01), the control group (P＜0.05), So there is efficiency on the treated group and the control group on increasing ALB; There is no statistical significance between the two groups on the 1 months (P＞0.05); There is statistical significancebetween the two groups on the 3 months (P＜0.05); explain that Shuganjianpi prescription has the prostecdtive efficacy in increasing ALB.5. hll of the patients of two groups were observed both before treatment and 1, 3 months after treatment, in the treated group, The level of the TBIL decreased gradually during the treatment, There is statistical significance (P＜0.05), So there is efficiency on the treated group on decreasing TBIL, in the control group, There is no statistical significance (P＞0.05); There is no statistical significance between the two groups on the 1 months (P＞0.05); There is statistical significancebetween the two groups on the 3 months (P＜0.05); explain that Shuganjianpi prescription has the prostecdtive efficacy in decreasing TBIL.6. After treatment, There is no statistical significance between each group on the ratio of A/G compared with prior treatment (P＞0.05); on the 1 and 3months after treatment, there is no statistical significance between the treated group and the control group (P＞0.05).7. There is no statistical significance between the treated group and the control group on the condition of abdominal ultrasonography (P＞0.05).8. After treatment, the quantitation of HBV-DNA decreased gradually during the treatment, There is no statistical significance between each group compared with prior treatment (P＞0.05); there is no statistical significance between the two groups (P＞0.05); After treatment, compared the clearance rate of HBV-DNA, the treated group is 9 cases (30.00%), the control group is 7 cases (23.33%), there is no statistical significance between the two groups (P＞0.05).Conclusion: Shuganjianpi prescription has the marked effect on improving the syndrome for the patient of Chronic Hepatitis B, especially in the syndromes of expanding of abdomen, inappetence, lassitude and taciturnity, restlessness and tantrum, mashed stool; At the aspect of Liver function, for the Shuganjianpi prescription, there is conspicuous curative effect on lowering ALT, there is prostecdtive efficacy in increasing ALB and decreasing TBIL, there is no conspicuous curative effect in raising A/G, improving the condition of abdominal ultrasonography, decreasing the quantitation of HBV-DNA and the clearance rate of HBV-DNA.
|
PDF Full Text Request